Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice

Heidi Liljenbäck; Erik S.G. Stroes; Sanna Hellberg; Johanna M.U. Silvola; Margreet de Vries; Nina Savisto; Juhani Knuuti; Petteri Rinne; Jeffrey Kroon; Tommy Abrahamsson; Mia Ståhle; Knut Pettersson; Pekka Saukko; Anne Roivainen; Seppo Ylä-Herttuala; Alwin de Jong; ; Antti Saraste; Paul H. A. Quax; Anna Wickman
Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice

Heidi Liljenbäck
Erik S.G. Stroes
Sanna Hellberg
Johanna M.U. Silvola
Margreet de Vries
Nina Savisto
Juhani Knuuti
Petteri Rinne
Jeffrey Kroon
Tommy Abrahamsson
Mia Ståhle
Knut Pettersson
Pekka Saukko
Anne Roivainen
Seppo Ylä-Herttuala
Alwin de Jong
Antti Saraste
Paul H. A. Quax
Anna Wickman
Katso/Avaa
Lataukset: 

Elsevier Inc
doi:10.1016/j.jacbts.2020.01.008
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021042823708
Tiivistelmä

This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of 18F-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies.

Kokoelmat